As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results.

Find the latest 3SBio Inc. (83B.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

About 3SBio Inc. 3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.

Find the latest 3SBIO (1530.HK) stock quote, history, news and other vital information to help you with your stock trading and investing.

3SBio Inc., based in Shenyang, China, said the joint venture disbanded after “certain conditions” in the agreement were not completed by an April 30 deadline. 3SBio had agreed last September ...

3SBio has good financial health. As of 2020, total debt was CNY 3 billion, net debt was minus CNY 218 million, and net debt to equity was negative 2%. The company generates approximately CNY 1 ...

3SBio has good financial health. As of 2019, total debt was CNY 2.8 billion, net debt was CNY 700 million, and net debt to equity was a mere 7%. We project 2020 operating cash flow at CNY 1.5 ...